A recent study in the Uppsala-Umeå Comprehensive Cancer Consortium (U-CAN) biobank measured 1463 proteins in treatment-naïve diagnostic plasma samples from 48 CLL, 55 DLBCL and 38 MM patients using Olink Explore PEA technology.29 Notable proteins associated with active disease included SLAMF7, MZB1, QPCT, BAFF and CNTN5 for MM, FCRL1, FCRL3, IGSF3, SEMA7A, SIGLEC6, TCL1A and sCD23 for CLL and SERPINA9 and CXCL13 for DLBCL. Here, SIGLEC6 is linked to diffuse large B-cell lymphoma.